grant

Targeting TGFb In Osteogenesis Imperfecta

Organization BAYLOR COLLEGE OF MEDICINELocation HOUSTON, UNITED STATESPosted 7 Sept 2023Deadline 30 Jun 2028
NIHUS FederalResearch GrantFY20250-11 years old21+ years oldAdultAdult HumanAffectAntibodiesArchitectureBindingBiomechanicsBisphosphonatesBone DevelopmentBone DysplasiasBone FormationBone callusBone-Derived Transforming Growth FactorBony CallusBrittle bone disorderCOL1A1COL1A1 geneCOL1A2COL1A2 geneCallusCell Communication and SignalingCell SignalingCell-Extracellular MatrixChildChild YouthChildren (0-21)ChondrocytesClinicalClinical ManagementClinical TrialsCollagenCollagen Type ICommon Rat StrainsCouplingDNA mutationDataDevelopmental Bone DiseasesDoseECMEngineering / ArchitectureExtracellular MatrixFDA approvedForteoFractureFracture HealingFragilitas OssiumFrequenciesFutureGenesGeneticGenetic ChangeGenetic defectGenetic mutationGoalsHealing abnormalHealing delayedHereditaryHistologyHumanHydroxylationImpaired healingIncidenceInflammationInheritedIntracellular Communication and SignalingLeadLeucineLong-Term EffectsMeasuresMiceMice MammalsMilk Growth FactorModelingModern ManModificationMolecular InteractionMurineMusMutationNational Institutes of HealthOsteoblastsOsteoclastsOsteogenesisOsteogenesis ImperfectOsteogenesis ImperfectaOutcomeParticipantPathway interactionsPatientsPb elementPhasePhenotypePhysiologic OssificationPhysiological OssificationPlatelet Transforming Growth FactorProcollagenProteoglycanRatRats MammalsRattusReceptor ProteinRecurrenceRecurrentRegimenSafetySamplingSerologySeveritiesSignal TransductionSignal Transduction SystemsSignalingSpinal ColumnSpineTGF BTGF-betaTGF-βTGFbetaTGFβTeriparatideTestingTherapeuticThickThicknessTibial FracturesToxicologyTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTumor CellType 1 CollagenType I ProcollagenUnited States National Institutes of HealthVertebral columnadulthoodangiogenesisbackbonebiological signal transductionbiomechanicalbiphosphonatebisphosphonatebonebone development disorderbone fracturebone fracture healingbone fracture repairbone massbone repairbone tissue formationbone turnoverbrittle bone diseasecombinatorialcrosslinkdecorindiphosphonateeffective therapyeffective treatmenteffectiveness studyfetalfracture repairgenome mutationhPTH (1-34)healingheavy metal Pbheavy metal leadimprovedinflammation markerinflammatory markerinnovateinnovationinnovativekidsmineralizationmouse modelmurine modelneoplastic cellnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnormal ossificationnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetoff-label applicationoff-label prescribingoff-label useossificationoverexpressoverexpressionpathwayphase 1 trialphase I trialprotein complexreceptorsafety testingskeletalstandard of carestructural mutationstructural variantstructural variationtargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttraffickingyoungster
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

PROJECT SUMMARY
Osteogenesis Imperfecta (OI) is a group of heterogeneous brittle bone disorders. Over 95% of patients

harbor dominantly inherited structural mutations in the type I procollagen genes (COL1A1 and COL1A2) or

recessively inherited mutations in the protein complexes important in type I collagen post-translational assembly

and…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Targeting TGFb In Osteogenesis Imperfecta — BAYLOR COLLEGE OF MEDICINE | UNITED STATES | Sept 2023 | Dev Procure